Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

Debiopharm S.A.. (1/13/15). "Press Release: Debiopharm Diagnostics Leads Investment Round in GenePOC with Emerillon Capital". Lausanne.

Organisations Organisation Debiopharm Diagnostics S.A.
  Group Debiopharm (Group)
  Organisation 2 GenePOC Inc. (CA)
Products Product real-time PCR technology
  Product 2 diagnostic test, rapid (point-of-care)
Index term Index term GenePOC–Debiopharm: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital
Persons Person Deperthes, David (Debiopharm 201306 VP Business Development)
  Person 2 Bergeron, Michel G. (Infectio Diagnostic 199501 founder)
     


Debiopharm Diagnostics, part of Debiopharm Group™, is proud to be the lead investor in GenePOC, who are developing a highly innovative, low cost and quick MDx (Molecular Diagnostics) platform. Debiopharm Diagnostics led this investment round together with Emerillon Capital and will become the largest shareholder in GenePOC.

Prof. Michel G. Bergeron, Director and Founder of the Infectious Disease Research Center at Université Laval and Founder of GenePOC, with his research group, conceived this simple microfluidic real-time PCR device that is easy for almost anyone to operate whether at bedside, in the emergency room, in physician offices, in pharmacies, or even in dispensaries in the developing world. "It fulfils my dream of moving from classical Pasteur microbiology taking up to two days, to near patient <1h diagnostic results which guide appropriate management of patients on the spot," says Dr. Bergeron.

"The investment in GenePOC confirms our strong belief in the future success of Point of Care technologies. GenePOC technology has the potential to be a game changer and should be on the market in 2016." said David Deperthes, CEO of Debiopharm Diagnostics.

"With GenePOC's platform we will be able to revolutionize diagnosis of infectious diseases. It addresses the critical issues of rapidity and affordability, to give the first viable alternative to the current standard and time-consuming approach of microbial culture. We are delighted to have Debiopharm Diagnostics and Emerillon Capital as key investors," said Patrice Allibert, CEO of GenePOC.

Ludovic André, Managing Director of Emerillon Capital added: "GenePOC has the capability to offer a simple and accurate solution for Point of Care testing, and at an affordable cost which is pre-requisite to democratize this emerging diagnostic area. Emerillon is proud to support this project driven by a world-class team in the field of molecular diagnostic."

"With the emergence of bacterial antibiotic resistance the treatment paradigm needs to be changed and the new generation of targeted antibiotics will require associated rapid low-cost diagnostics. Our Group will continue to invest on both therapeutic and diagnostic sides to tackle this important issue," stated Thierry Mauvernay, Delegate of the Board, Debiopharm Group™.


About Debiopharm Diagnostics SA

Debiopharm Diagnostics' mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. Since 2008, Debiopharm Diagnostics has invested over USD 85 million and led 9 out of the 13 last investment rounds in its portfolio companies.
For more information, please visit: www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews


About GenePOC

Located in Québec city, Canada, GenePOC Inc. is a privately owned company that develops cost-effective and rapid molecular devices to detect genes at Point-of-Care. GenePOC has developed a simple and integrated portable instrument for the prevention and early detection of infectious diseases based on a unique centripetal technology platform. For more: www.genepoc-diagnostics.com/Home.shtml


About Emerillon Capital

Launched in Montreal in June 2013, Emerillon Capital is a $100M venture capital fund empowered by a strong transatlantic partnership between Groupe Crédit Mutuel – CIC and Mouvement Desjardins. Emerillon Capital is dedicated to support and develop technology companies in Canada and the northeastern USA.
For more: http://emerilloncapital.com/en/


Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel: +41 (0)21 321 01 11

GenePOC Contact
Patrice Allibert
CEO
patrice.allibert@genepooc.ca
Tel: +1 418 650 3535

Emerillon Contact
Claude Kellenny
Claude.kellenny@emerilloncapital.com
Tel : +1 514 281 2282

Additional Media Contacts

In London
Maitland
Brian Hudspith
bhudspith@maitland.co.uk
Tel: +44 (0)20 7379 5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
martina.schwarzkopf@russopartnersllc.com
Tel: +1 212-845-4292

   
Record changed: 2016-04-23

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for Debiopharm (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpa




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 Barcelona 120x240px wpssy Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px